Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...
A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The ...
Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...
Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...
While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...